Second Quarter 2026 financial results Financial highlights for the quarter include the following: Detail of the revenue The Q2 2026 revenue is related to a feasibility study on a novel peptide combination using BioChaperone performed with an undisclosed potential partner
Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES , Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R
Weight Loss IV Therapy offers a targeted boost, delivering a potent blend of fat-burning nutrients like Vitamin B12, MIC, and Taurine directly into your bloodstream
Best to refrigerate this product after opening